Compile Data Set for Download or QSAR
Report error Found 240 Enz. Inhib. hit(s) with all data for entry = 11485
TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620313(tert-butyl ((5r,8R)-3-(((2R,3R,4S,5R,6R)-4-(4-(4-c...)
Affinity DataIC50: 10nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620309(tert-butyl ((5r,8R)-3-(((2R,3R,4S,5R,6R)-5-hydroxy...)
Affinity DataIC50: 12nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620311(US20230295182, Example 1.44 | tert-butyl ((5r,8R)-...)
Affinity DataIC50: 15nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620359(US20230295182, Example 2.09 | ethyl ((5r,8R)-3-(((...)
Affinity DataIC50: 17nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620361(US20230295182, Example 2.11 | ethyl ((5r,8R)-3-(((...)
Affinity DataIC50: 19nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620360(US20230295182, Example 2.10 | ethyl ((5r,8R)-3-(((...)
Affinity DataIC50: 20nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620283(tert-butyl ((5r,8R)-3-(((2R,3R,4S,5R,6R)-5-hydroxy...)
Affinity DataIC50: 35nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620383(US20230295182, Example 3.02 | 3-(((2R,3R,4S,5R,6R)...)
Affinity DataIC50: 36nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620375(US20230295182, Example 2.25 | 2-(((2R,3R,4S,5R,6R)...)
Affinity DataIC50: 37nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620325(US20230295182, Example 1.57 | (5r,8R)-3-(((2R,3R,4...)
Affinity DataIC50: 41nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620385(US20230295182, Example 4.01 | 3-(((2R,3R,4S,5R,6R)...)
Affinity DataIC50: 46nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620329(US20230295182, Example 1.61 | (5r,8R)-3-(((2R,3R,4...)
Affinity DataIC50: 49nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620350(US20230295182, Example 1.82 | (2R,3R,4S,5R,6R)-6-(...)
Affinity DataIC50: 50nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620358(US20230295182, Example 2.08 | N-((5r,8R)-3-(((2R,3...)
Affinity DataIC50: 52nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620349(US20230295182, Example 1.81 | (2R,3R,4S,5R,6R)-6-(...)
Affinity DataIC50: 60nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620313(tert-butyl ((5r,8R)-3-(((2R,3R,4S,5R,6R)-4-(4-(4-c...)
Affinity DataIC50: 60nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620354(US20230295182, Example 2.04 | N-((5r,8R)-3-(((2R,3...)
Affinity DataIC50: 61nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620141(US20230295182, Example 1.01 | (2R,3R,4S,5R,6R)-2-(...)
Affinity DataIC50: 61nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620357(US20230295182, Example 2.07 | N-((5r,8R)-3-(((2R,3...)
Affinity DataIC50: 62nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620304(US20230295182, Example 1.36 | (2R,3R,4S,5R,6R)-6-(...)
Affinity DataIC50: 64nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620279(US20230295182, Example 1.11 | tert-butyl (3-(((2R,...)
Affinity DataIC50: 69nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620356(US20230295182, Example 2.06 | N-((5r,8R)-3-(((2R,3...)
Affinity DataIC50: 71nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620386(US20230295182, Example 4.02 | 2-(((2R,3R,4S,5R,6R)...)
Affinity DataIC50: 74nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620387(US20230295182, Example 4.03 | (2R,3R,4S,5R,6R)-4-(...)
Affinity DataIC50: 74nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620290(US20230295182, Example 1.22 | (2R,3R,4S,5R,6R)-6-(...)
Affinity DataIC50: 76nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620282(US20230295182, Example 1.14 | (2R,3R,4S,5R,6R)-6-(...)
Affinity DataIC50: 78nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620215(US20230295182, Example 1.03 | (2R,3R,4S,5R,6R)-2-(...)
Affinity DataIC50: 79nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620374(US20230295182, Example 2.24 | 2-(((2R,3R,4S,5R,6R)...)
Affinity DataIC50: 80nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620294((2R,3R,4S,5R,6R)-6-((8,8-difluoro-1-oxa-2-azaspiro...)
Affinity DataIC50: 81nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620388(US20230295182, Example 4.04 | (2R,3R,4S,5R,6R)-6-(...)
Affinity DataIC50: 81nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620204(US20230295182, Example 1.02 | (2R,3R,4R,5R,6R)-2-(...)
Affinity DataIC50: 84nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620308(US20230295182, Example 1.40 | (5r,8R)-3-(((2R,3R,4...)
Affinity DataIC50: 89nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620384(US20230295182, Example 3.03 | 3-(((2R,3R,4S,5R,6R)...)
Affinity DataIC50: 90nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620328(US20230295182, Example 1.60 | (5s,8S)-3-(((2R,3R,4...)
Affinity DataIC50: 90nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620376(US20230295182, Example 2.26 | 2-(((2R,3R,4S,5R,6R)...)
Affinity DataIC50: 90nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620319(US20230295182, Example 1.51 | 3-(((2R,3R,4S,5R,6R)...)
Affinity DataIC50: 100nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620311(US20230295182, Example 1.44 | tert-butyl ((5r,8R)-...)
Affinity DataIC50: 100nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620345(US20230295182, Example 1.77 | (RS)-3-(((2R,3R,4S,5...)
Affinity DataIC50: 100nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620303(US20230295182, Example 1.35 | (2R,3R,4S,5R,6R)-6-(...)
Affinity DataIC50: 110nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620289(US20230295182, Example 1.21 | (2R,3R,4S,5R,6R)-6-(...)
Affinity DataIC50: 110nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620370(US20230295182, Example 2.20 | (2R,3R,4S,5R,6R)-6-(...)
Affinity DataIC50: 110nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620317(US20230295182, Example 1.49 | 3-(((2R,3R,4S,5R,6R)...)
Affinity DataIC50: 110nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620344(US20230295182, Example 1.76 | (RS)-3-(((2R,3R,4S,5...)
Affinity DataIC50: 110nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620341(US20230295182, Example 1.73 | (2R,3R,4S,5R,6R)-2-(...)
Affinity DataIC50: 110nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620294((2R,3R,4S,5R,6R)-6-((8,8-difluoro-1-oxa-2-azaspiro...)
Affinity DataIC50: 110nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620326(US20230295182, Example 1.58 | (5s,8S)-3-(((2R,3R,4...)
Affinity DataIC50: 110nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620288(US20230295182, Example 1.20 | (2R,3R,4S,5R,6R)-6-(...)
Affinity DataIC50: 120nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620305(US20230295182, Example 1.37 | (2R,3R,4S,5R,6R)-6-(...)
Affinity DataIC50: 120nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620333(US20230295182, Example 1.65 | (2R,3R,4S,5R,6R)-4-(...)
Affinity DataIC50: 120nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620382(US20230295182, Example 3.01 | tert-butyl 3-(((2R,3...)
Affinity DataIC50: 120nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

Displayed 1 to 50 (of 240 total ) | Next | Last >>
Jump to: